Quarter 3 results Eli Lilly reported a 54% increase in revenue in the third quarter, rising to $17.60 billion in 2025 from $11.439 billion in 2024, which the company largely credited to sales of Mounjaro and Zepbound, the company’s GLP-1 agonist weight-loss treatments. Mounjaro revenue saw a 109% increase in revenue from the third quarter… The post Eli Lilly announces Q3 results, $3 billion new site, plans for oral GLP-1 approval appeared first on Drug Discovery and Development.| Drug Discovery and Development
Eli Lilly is on track to overtake pharma rivals and claim the industry’s top spot by late 2026, completing one of the most dramatic repositionings in Big Pharma’s recent history. Aggressive and base scenarios place Lilly’s rise to the number one slot in 2026, while a conservative prediction forecasts that the firm will do so… The post Lilly is set to lead pharma in 2026, but can it justify an $800B valuation? appeared first on Drug Discovery and Development.| Drug Discovery and Development
It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%… The post Trump’s $150 Ozempic vow hits Novo, Lilly, even as Oz says ‘we have not negotiated those yet’ appeared first on Drug Discovery and Dev...| Drug Discovery and Development
Novo Nordisk has agreed to acquire Akero Therapeutics, a clinical-stage company that develops treatments for metabolic diseases, the company announced last week. Akero’s EFX pipeline Akero Therapeutics’ treatment for metabolic-dysfunction-associated steatohepatitis (MASH) “is closely linked with Novo Nordisk’s expertise in diabetes and obesity,” the press release stated. More than 40% of patients with MASH, formerly… The post Novo Nordisk to acquire Akero Therapeutics for $5.2 b...| Drug Discovery and Development